This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 102/6/686    most recent CIRCRESAHA.107.163428v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Evans-Anderson, H. J. Articles by Yutzey, K. E. PubMed PubMed Citation Articles by Evans-Anderson, H. J. Articles by Yutzey, K. E. Related Collections Developmental biology Gene expression Gene regulation Genetically altered mice Growth factors/cytokines Myogenesis Physiological and pathological control of gene expression

(Circulation Research. 2008;102:686.)
© 2008 American Heart Association, Inc.

Cellular Biology

Regulation of Cardiomyocyte Proliferation and Myocardial Growth During Development by FOXO Transcription Factors

Heather J. Evans-Anderson, Christina M. Alfieri, Katherine E. Yutzey

From the Division of Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center, Ohio.

Correspondence to Division of Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229. E-mail yutzey{at}cchmc.org

Cardiomyocytes actively proliferate during embryogenesis and withdraw from the cell cycle during neonatal stages. FOXO (Forkhead O) transcription factors are a direct target of phosphatidylinositol-3 kinase/AKT signaling in skeletal and smooth muscle and regulate expression of the Cip/Kip family of cyclin kinase inhibitors in other cell types; however, the interaction of phosphatidylinositol-3 kinase/AKT signaling, FOXO transcription factors, and cyclin kinase inhibitor expression has not been reported for the developing heart. Here, we show that FOXO1 and FOXO3 are expressed in the developing myocardium concomitant with increased cyclin kinase inhibitor expression from embryonic to neonatal stages. Cell culture studies show that embryonic cardiomyocytes are responsive to insulin-like growth factor 1 stimulation, which results in the induction of the phosphatidylinositol-3 kinase/AKT pathway, cytoplasmic localization of FOXO proteins, and increased myocyte proliferation. Likewise, adenoviral-mediated expression of AKT promotes cardiomyocyte proliferation and cytoplasmic localization of FOXO. In contrast, increased expression of FOXO1 negatively affects myocyte proliferation. In vivo myocyte-specific transgenic expression of FOXO1 during heart development causes embryonic lethality at embryonic day 10.5 because of severe myocardial defects that coincide with premature activation of p21^cip1, p27^kip1, and p57^kip2 and decreased myocyte proliferation. Transgenic expression of dominant negative FOXO1 in cardiomyocytes does not obviously affect heart development at embryonic day 10.5, but results in abnormal morphology of the myocardium by embryonic day 18.5 along with decreased cyclin kinase inhibitor expression and increased myocyte proliferation. These data support FOXO transcription factors as negative regulators of cardiomyocyte proliferation and promoters of neonatal cell cycle withdrawal during heart development.

Key Words: heart development • FOXO1 (FKHR) • Cip/Kip cyclin kinase inhibitors